"It made me more confident that I have it under control": Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain.
Wendy DavisAndrea MantsiosTahilin KarverMiranda MurrayYogesh PunekarDouglas WardU Fritz BredeekSantiago MorenoDolores MerinoHernando KnobelAntonio CampisDeanna KerriganPublished in: PloS one (2020)
Participants' experiences with a 2DR regimen were positive with no participants, reporting side effects and all reporting continued viral suppression. Providers valued the reduced toxicity offered by 2DR and served as the primary gateway to a transition to 2DR for patients in both settings. This study provides a foundation for further research on the transition to 2DR regimens in other populations and contexts including low- and middle-income settings.